Debio 2511
The Debio 2511 program is a potential 1st-in-class bispecific ADC integrating our proprietary Multilink™ Linker Technology and targeting a yet-to-be disclosed combination of antigens.
Debiopharm’s ADC expertise
We’re developing fit-for-purpose antibody drug conjugates through a tailored “Trifecta” approach: strategic target selection, innovative Multilink™ linker technology and smart payload choices. We are continuing to invest in our ADC platform, exploring potential game changing technologies such as novel and multiple payloads, leveraging our solid development experience to accelerate ADC products to patients.
